Cardium Therapeutics has completed the second tranche of its previously announced registered direct offering consisting of an additional 1,656 shares of Series A convertible preferred stock for gross proceeds of approximately $1.7 million, bringing the total gross proceeds of the offering to approximately $4.0 million.
For a detailed description of the terms of the securities purchase agreement as well as the rights, privileges, and preferences of the Series A Convertible Preferred Stock, view CXM's current report on Form 8-K here: dtg.fm/45Ml.
CXM is an asset-based health sciences and regenerative medicine company engaged in the acquisition and strategic development of products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization.
For more information, visit cardiumthx.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net